公开(公告)号：US11951141B2

公开(公告)日：2024-04-09

申请号：US17091549

申请日：2020-11-06

申请人： MEMGEN, Inc. ,  H. Lee Moffitt Cancer Center and Research Institute, Inc.

发明人： Mark J. Cantwell ,  Amer A. Beg

IPC分类号： A61K35/761 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/22

CPC分类号： A61K35/761 ,  A61P35/00 ,  C12N7/00 ,  C12N2710/10021 ,  C12N2710/10032 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2830/00

摘要： Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.

公开(公告)号：US11739345B2

公开(公告)日：2023-08-29

申请号：US16407015

申请日：2019-05-08

申请人： BIOMARIN PHARMACEUTICAL INC.

发明人： Geoffrey Berguig ,  Rajeev Mahimkar ,  Hassibullah Akeefe ,  Peter Colosi

IPC分类号： C12N15/864 ,  C12N15/12 ,  C12N15/63 ,  A61K48/00 ,  C12N7/01 ,  C12N7/02 ,  C12N15/86 ,  A61P3/00 ,  C12N7/00 ,  G01N33/94

CPC分类号： C12N15/86 ,  A61K48/0066 ,  A61P3/00 ,  C12N7/00 ,  G01N33/9406 ,  C12N2830/50

摘要： Provided herein are methods of treating phenylketonuria by normalizing levels of amino acids, neurotransmitters, and neurotransmitter metabolites in a subject having phenylketonuria.

公开(公告)号：US11248036B2

公开(公告)日：2022-02-15

申请号：US16717373

申请日：2019-12-17

申请人： Washington University

发明人： Christopher Nelson ,  Steven Teitelbaum ,  Daved Fremont ,  Julia T. Warren

IPC分类号： C07K14/705 ,  C12N15/12 ,  C12N15/63 ,  A61K38/00

摘要： Methods for constructing efficient inhibitors of target TNF superfamily receptors, single chain target TNF superfamily ligands that inhibit of target TNF superfamily receptors while failing to engage or inhibit non-target TNF superfamily receptors, and methods of their use to treat diseases are provided. Single chain RANKL, TNF, and TRAIL ligands that effectively inhibit their target receptors while failing to inhibit non-target TNF superfamily receptors are also provided.

公开(公告)号：US11180758B2

公开(公告)日：2021-11-23

申请号：US16078760

申请日：2017-02-24

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： David Lee Thomas ,  Ashwin Balagopal ,  Ramy El-Diwany ,  Robert Siliciano ,  Joel Blankson ,  Stuart C Ray ,  Michel Anand Chattergoon ,  Justin Bailey

IPC分类号： C12N15/12 ,  A61K38/00 ,  C12N15/113 ,  A61K38/45 ,  A61K38/17 ,  A61P31/18

摘要： Three proteins, BCL-G (BCL2L14), CMPK2, and LAMP3, were discovered to independently restrict HIV-1 replication both in-vivo and in-vitro. Methods are described wherein subjects are given an effective amount of a pharmaceutical composition comprising a protein selected from the group consisting of BCL-G, CMPK2, LAMP3, functional parts thereof, recombinant proteins thereof, and combinations thereof, for the purpose of treating or preventing HIV.

公开(公告)号：US11180754B2

公开(公告)日：2021-11-23

申请号：US16425897

申请日：2019-05-29

申请人： CJ CHEILJEDANG CORPORATION

发明人： Jung Gun Kwon ,  Min Ji Baek ,  Ji Hye Lee ,  Nara Kwon ,  Ju Jeong Kim ,  Jin Ah Rho ,  Jin Man Cho

IPC分类号： C12N15/12 ,  C12N15/11 ,  C07K14/34 ,  C07K14/705 ,  C12N1/20 ,  C12P19/32 ,  C12N15/77 ,  C12R1/15

摘要： The present disclosure relates to a novel polypeptide having an activity of exporting 5′-inosine monophosphate, a microorganism comprising the same, a method for preparing 5′-inosine monophosphate using the same, and a method for increasing export of 5′-inosine monophosphate.

公开(公告)号：US10711296B2

公开(公告)日：2020-07-14

申请号：US15550559

申请日：2016-03-24

申请人： SIGMA-ALDRICH CO. LLC

发明人： Kenneth B Heuermann ,  Carol A Kreader ,  Jaime K Robert ,  Brian W Ward

IPC分类号： C12Q1/6806 ,  C12Q1/6853 ,  C12N15/10 ,  C12N15/12

摘要： Processes, oligonucleotides, and kits for amplifying RNA. In particular, the processes generate and amplify cDNA libraries in which the orientation of the input RNA molecule is preserved in the products. Among the various aspects of the present disclosure is the provision of process for directionally amplifying RNA. The process comprises reverse transcribing at least one RNA molecule in the presence of a plurality of first synthesis primers to generate a plurality of first strands of complementary DNA (cDNA), wherein each of the first synthesis primers comprises a 3′ sequence having complementarity to a portion of the RNA molecule, a non-complementary 5′ sequence corresponding to one or more amplification primers, and optionally an internal tag sequence comprising a first tag sequence.

公开(公告)号：US10662235B2

公开(公告)日：2020-05-26

申请号：US15629090

申请日：2017-06-21

申请人： Janssen Biotech, Inc.

发明人： Mark Anderson ,  Ricardo Attar ,  Michael Diem ,  Linus Hyun ,  Alastair King ,  Steven Jacobs ,  Shalom Goldberg ,  Donna Klein ,  Sheri Moores ,  Karyn O'Neil ,  Kristen Picha

IPC分类号： C07K14/71 ,  C07K14/78 ,  C07K19/00 ,  C12N15/09 ,  C12N15/12 ,  C12N15/63 ,  C12N15/64

摘要： Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US10604565B2

公开(公告)日：2020-03-31

申请号：US15912358

申请日：2018-03-05

申请人： JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG

发明人： Jörg Wischhusen ,  Markus Junker ,  Tina Schäfer ,  Dirk Pühringer

IPC分类号： C07K16/22 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/18 ,  C12N5/10 ,  C12N15/12 ,  C12N15/13 ,  C12N15/63

摘要： The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

公开(公告)号：US10392431B2

公开(公告)日：2019-08-27

申请号：US15430977

申请日：2017-02-13

申请人： St. Jude Children's Research Hospital

发明人： Dario A.A. Vignali ,  Lauren Collison

IPC分类号： C12N15/12 ,  C07K14/715 ,  C07K16/24 ,  C12Q1/6883 ,  C12Q1/6886 ,  C07K16/28 ,  G01N33/50 ,  A61K39/00

摘要： The receptor for Interleukin 35 (IL-35) is provided. The Interleukin 35 Receptor (IL-35R) comprises a heterodimeric complex of the Interluekin12Rβ2 receptor and the gp130 receptor. Various compositions comprising the IL-35R complex, along with polynucleotides encoding the same and kits and methods for the detection of the same the same are provided. Methods of modulating the activity of IL-35R or modulating effector T cell functions are also provided. Such methods employ various IL-35R antagonists and agonists that modulate the activity of the IL-35R complex and, in some embodiments, modulate effector T cell function. Further provided are methods for screening for IL-35R binding agents and for IL-35R modulating agents. Various methods of treatment are further provided.

公开(公告)号：US10189907B2

公开(公告)日：2019-01-29

申请号：US15361936

申请日：2016-11-28

申请人： Celldex Therapeutics, Inc.

发明人： Yaron Hadari ,  Susanne Radke ,  Joseph Schlessinger ,  Yoshihisa Suzuki

IPC分类号： C12N15/13 ,  C12N15/09 ,  C12N15/11 ,  C12N15/12 ,  C07K16/28 ,  A61K39/395 ,  C12N9/24 ,  G01N33/68 ,  A61K45/06 ,  G01N33/573 ,  A61K47/68 ,  A61K39/00

摘要： Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.